FOLD icon

Amicus Therapeutics

6.43 USD
+0.48
8.07%
At close May 16, 4:00 PM EDT
After hours
6.39
-0.04
0.62%
1 day
8.07%
5 days
4.21%
1 month
-4.03%
3 months
-34.72%
6 months
-33.44%
Year to date
-30.93%
1 year
-32.32%
5 years
-49.01%
10 years
-41.39%
 

About: Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Employees: 499

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

4% more repeat investments, than reductions

Existing positions increased: 105 | Existing positions reduced: 101

2% less call options, than puts

Call options by funds: $4.77M | Put options by funds: $4.87M

7% less first-time investments, than exits

New positions opened: 39 | Existing positions closed: 42

1.36% less ownership

Funds ownership: 103.45% [Q3] → 102.09% (-1.36%) [Q4]

2% less funds holding

Funds holding: 287 [Q3] → 282 (-5) [Q4]

12% less capital invested

Capital invested by funds: $3.28B [Q3] → $2.87B (-$403M) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 6 [Q3] → 4 (-2) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$9
40%
upside
Avg. target
$16
149%
upside
High target
$22
242%
upside

3 analyst ratings

positive
67%
neutral
33%
negative
0%
UBS
Karl Chalabala
0% 1-year accuracy
0 / 2 met price target
242%upside
$22
Buy
Maintained
2 May 2025
Goldman Sachs
Salveen Richter
27% 1-year accuracy
3 / 11 met price target
40%upside
$9
Neutral
Maintained
2 May 2025
Wells Fargo
Tiago Fauth
31% 1-year accuracy
8 / 26 met price target
164%upside
$17
Overweight
Maintained
20 Feb 2025

Financial journalist opinion

Based on 9 articles about FOLD published over the past 30 days

Neutral
GlobeNewsWire
1 week ago
Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2025 Health Care Conference in Las Vegas, NV on Wednesday, May 14, 2025, at 8:00 a.m.
Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference
Negative
Zacks Investment Research
2 weeks ago
FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls
Amicus' first-quarter 2025 earnings and sales miss estimates. Shares decline.
FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls
Neutral
Seeking Alpha
2 weeks ago
Amicus Therapeutics, Inc. (FOLD) Q1 2025 Earnings Call Transcript
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President of Investor Relations Bradley Campbell - President & Chief Executive Officer Sebastien Martel - Chief Business Officer Jeffrey Castelli - Chief Development Officer Simon Harford - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Joshua Fleishman - TD Cowen Dennis Ding - Jefferies Kristen Kluska - Cantor Fitzgerald Gil Blum - Needham & Company Operator Good morning, ladies and gentlemen and welcome to the Amicus Therapeutics First Quarter 2025 Financial Results Conference Call and Webcast. At this time, participants are in a listen-only mode.
Amicus Therapeutics, Inc. (FOLD) Q1 2025 Earnings Call Transcript
Negative
Zacks Investment Research
2 weeks ago
Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.02 per share a year ago.
Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates
Neutral
GlobeNewsWire
2 weeks ago
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
1Q 2025 Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for Rare Kidney Disease with Significant Market Potential in the U.S. Maintaining 2025 Guidance for Galafold, Reflecting Strong Underlying Demand Updating 2025 Pombiliti + Opfolda Guidance with New Patient Starts Accelerating in 2H Adjusting 2025 Total Revenue Growth Guidance to 15-22% at CER Reiterating GAAP Profitability During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J.
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
Neutral
GlobeNewsWire
2 weeks ago
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS)
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
Neutral
Zacks Investment Research
3 weeks ago
Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Neutral
GlobeNewsWire
3 weeks ago
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025
PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2025.
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025
Positive
Zacks Investment Research
4 weeks ago
4 Healthcare Stocks to Buy as the Sector Faces Government Heat
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.
4 Healthcare Stocks to Buy as the Sector Faces Government Heat
Neutral
Zacks Investment Research
1 month ago
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
Charts implemented using Lightweight Charts™